Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations
- 31 October 2010
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 5 (10), 1551-1558
- https://doi.org/10.1097/jto.0b013e3181e9da60
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFRThe Journal of Molecular Diagnostics, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung CancerClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)British Journal of Cancer, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancerBritish Journal of Cancer, 2006
- A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung CancerThe Journal of Molecular Diagnostics, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004